<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02945722</url>
  </required_header>
  <id_info>
    <org_study_id>1608170</org_study_id>
    <secondary_id>2016-004381-25</secondary_id>
    <nct_id>NCT02945722</nct_id>
  </id_info>
  <brief_title>Study of the Impact of a Targeted Decolonization of S. Aureus Persistent Carriers</brief_title>
  <acronym>CIBERSTAPH</acronym>
  <official_title>Study of the Impact of a Targeted Decolonization of S. Aureus Persistent Carriers on the Occurrence of S. Aureus Infections in Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      S. aureus nasal carriage is a well-known risk factor for S. aureus infections in hemodialysis
      (HD) patients. Strains of carriage and infections are the same in &gt;80% of cases We recently
      shown that persistent carriers of S. aureus, not intermittent ones are at increased risk of
      staphylococcal infections in HD. Thanks to a new algorithm developped based on one nasal
      sample the determination of carriage status (persistent, intermittent or non-carriers) among
      patients is easy. Mupirocin use in HD have been shown to reduce significantly S. aureus
      infections however, multiples schedules of decolonization have been proposed to all S. aureus
      carriers. To date, there is no national guideline for decolonization of S. aureus in HD. We
      showed that only 50% of HD centers in France propose screening and decolonization of S.
      aureus carriers. The aim of the study is therefore to evaluate the impact of a targeted
      decolonization of S. aureus persistent carriers using mupirocin nasal ointment and
      chlorhexidine baths during 5 days on the occurrence of S. aureus infections in HD patients
      compared to the absence of decolonization using a randomized open study methodology.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hemodialysis patients will be randomized in 2 arms: one arm where persistent carriers will be
      decolonized. Decolonization schedule associate the use of mupirocin nasal ointment 3 times a
      day and chlorhexidine bath once a day for 5 days. Screening of persistent carriers in this
      arm will be done every 3 months and a new decolonization will be proposed to patients found
      (again) persistent carriers. Determination of carriage status will be done using one nasal
      swab by following the algorithm previously described. Bacterial load will be determined by a
      quantitative S. aureus PCR (Polymerase Chain Reaction) : persistent carriers are the patient
      with a bacterial load &gt; 103 CFU/mL (Colony Forming Unit) .

      The other arm is HD patients in which decolonization is not performed including impersistent
      carriers.

      All infections that occurred in enrolled patients will be counted in both groups
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>All infections will be reviewed by a Clinical Adjudication Comitee</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>S. aureus infection</measure>
    <time_frame>12 months</time_frame>
    <description>Number of S. Aureus define by Centers for Disease Control</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>endogenous S. aureus infections</measure>
    <time_frame>12 months</time_frame>
    <description>same strain of carriage and infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacteremias S. aureus</measure>
    <time_frame>12 months</time_frame>
    <description>Impact of Bacteremias S. aureus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>strain of S. aureus</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of resistants strains of S. aureus at mupirocin and chlorhexidine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>persistents carriers of S. aureus</measure>
    <time_frame>Months : 3, 6, 9, 12</time_frame>
    <description>Percentage of persistents carriers of S. aureus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intermittents carriers of S. aureus</measure>
    <time_frame>Months : 3, 6, 9, 12</time_frame>
    <description>Percentage of intermittents carriers of S. aureus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non-carriers carriers of S. aureus</measure>
    <time_frame>Months : 3, 6, 9, 12</time_frame>
    <description>Percentage of non-carriers carriers of S. aureus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>other bacterial infections</measure>
    <time_frame>12 months</time_frame>
    <description>Impact of other bacterial infections without S. aureus</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">850</enrollment>
  <condition>Hemodialysis Patients</condition>
  <arm_group>
    <arm_group_label>Decolonization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>persistent carriers will be decolonized. Decolonization schedule associate the use of mupirocin nasal ointment 3 times a day and chlorhexidine bath once a day for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No decolonization</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>HD patients in which decolonization is not performed including impersistent carriers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decolonization</intervention_name>
    <description>Decolonization schedule associate the use of mupirocin nasal ointment 3 times a day and chlorhexidine bath once a day for 5 days. Screening of persistent carriers will be done every 3 months</description>
    <arm_group_label>Decolonization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No decolonization</intervention_name>
    <description>Screening of persistent carriers in this arm will be done every 3 months</description>
    <arm_group_label>No decolonization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (age ≥ 18 years-old)

          -  Patient under chronic hemodialysis

          -  Patent that accepted to participate in the study with a written consent form signed

        Exclusion Criteria:

          -  Patients under peritoneal dialysis

          -  Patients with an active infection at the time of inclusion

          -  Patients previously treated by mupirocin and chlorhexidine for decolonization purpose

          -  Patients that received antimicrobials active on S. aureus during the month before the
             inclusion

          -  Patients with allergy to mupirocin or chlorhexidine

          -  Patients treated by hemodialysis transiently (non-terminal kidney failure)

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabeth Botelho-Nevers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU SAINT-ETIENNE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elisabeth Botelho-Nevers, MD</last_name>
    <phone>(0)477829234</phone>
    <phone_ext>+33</phone_ext>
    <email>elisabeth.botelho-nevers@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arnauld GARCIN, CRA</last_name>
    <phone>(0)477120286</phone>
    <phone_ext>+33</phone_ext>
    <email>arnauld.garcin@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH d'Annecy-Genevois</name>
      <address>
        <city>Annecy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Benoît FRANKO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ch Annonay</name>
      <address>
        <city>Annonay</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Carole DEPRELE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ch Cannes</name>
      <address>
        <city>Cannes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Manuela DODOI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AGDUC</name>
      <address>
        <city>La Tronche</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Nadège MINGAT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Emile Roux</name>
      <address>
        <city>Le Puy-en-Velay</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marc BOUILLER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Viorica BARBU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aural</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jean-Christophe SZELAG, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH St-Joseph St-Luc</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Cécile CHAUVET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Laurent JUILLARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AIDER Santé</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Nathalie RAYNAL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cécile GUIRAUD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Roanne</name>
      <address>
        <city>Roanne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Aurore SURY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ARTIC42</name>
      <address>
        <city>Saint Etienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jacques JURINE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aida AFIANI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Linda AZZOUZ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aline CHABROUX-SEFFERT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Saint-Etienne</name>
      <address>
        <city>Saint-etienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elisabeth BOTHELO-NEVERS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amandine GAGNEUX-BRUNON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fréderic LUCHT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe BERTHELOT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florence GRATTARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul VERHOEVEN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne CARRICAJO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Damien THIBAUDIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric ALAMARTINE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe MARIAT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hesham MOHEY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NephroCare</name>
      <address>
        <city>Sainte-foy-les-Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Manolie MEHDI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2016</study_first_submitted>
  <study_first_submitted_qc>October 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2016</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemodialysis</keyword>
  <keyword>S. Aureus</keyword>
  <keyword>Decolonization</keyword>
  <keyword>Persistent carriage</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

